Annual Meeting Abstracts

0414-annual-meeting-on-Womens-cancer

Annual Meeting > Abstracts

2016 SGO Annual Meeting Abstracts

Abstract titles, authors and institutions are available through the online Annual Meeting schedule.

2016 SGO Annual Meeting Late-Breaking Abstracts

The Late-Breaking Abstracts have been selected for the Society of Gynecologic Oncology’s 2016 Annual Meeting on Women’s Cancer. The most current data from the following studies will be presented on Monday, March 21:

  • Analysis of the neoadjuavant arm of CHORUS: A response after three cycles of first-line platinum chemotherapy in advanced ovarian cancer
  • A prospective randomized trial comparing colorimetric and fluorescent imaging for pelvic sentinel lymph node mapping in endometrial cancer
  • The preliminary results of a phase II study: PD-1 blockade in mismatch repair–deficient, recurrent, or persistent endometrial cancer
  • NRG Oncology/Gynecologic Oncology 186K: The final results of a randomized phase II study of NCI-supplied cabozantinib vs. weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
  • NRG/GOG study showing disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival
  • An NRG study on a phase III trial of bevacizumab with IV vs. IP chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma
  • Patient-reported outcomes in GOG 252: An NRG Oncology Study of IV vs. IP chemotherapy for ovarian, fallopian, or peritoneal carcinoma